MEG
MRVI icon

Millstone Evans Group’s Maravai LifeSciences MRVI Stock Holding History

Millstone Evans Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458 Hold
162
– – ﹤0.01% 833
2025
Q4 		$527 Hold
162
– – ﹤0.01% 834
2025
Q3 		$465 Hold
162
– – ﹤0.01% 818
2025
Q2 		$390 Hold
162
– – ﹤0.01% 750
2025
Q1 		$358 Hold
162
– – ﹤0.01% 778
2024
Q4 		$883 Buy
+162
New +$1.04K ﹤0.01% 691

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millstone Evans Group's MRVI Position: Q1 2026 in Review

Millstone Evans Group held its Maravai LifeSciences (MRVI) position steady in Q1 2026 at 162 shares worth $458. The position accounts for ﹤0.01% of the portfolio, ranked #833.

Millstone Evans Group first reported a position in MRVI in Q4 2024 and has held it in 6 quarters since. The position peaked at $883 in Q4 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Millstone Evans Group held 162 shares of Maravai LifeSciences worth $458 as of Q1 2026.
  • Millstone Evans Group left its Maravai LifeSciences share count unchanged in Q1 2026.
  • Maravai LifeSciences made up ﹤0.01% of Millstone Evans Group's portfolio in Q1 2026, its #833 holding.
  • Millstone Evans Group first reported a position in Maravai LifeSciences in Q4 2024 and has held it in 6 quarters since.
  • Millstone Evans Group's Maravai LifeSciences position peaked at $883 in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Millstone Evans Group's 13F filing for Q1 2026, filed 30 Apr 2026.